Syros Pharmaceuticals Inc (SYRS NASDAQ) stock market data APIs
$0.2166
-0.02(-8.4%)
as of January 14, 2025
Syros Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Prev. Close
0.2376
Open
0.2166
Volume
1 462 K
High
0.2429
Low
0.2093
52 wk Range
0.183-7.96
Market Cap
6 375 K
Shares Outstanding
26 833 K
Revenue
386 K
EPS
-0.16
Beta
1.592
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Syros Pharmaceuticals Inc data using free add-ons & libraries
Get Syros Pharmaceuticals Inc Fundamental Data
Syros Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 386 K
- EBITDA: -110 180 000
- Earnings Per Share: -3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-10-31
- EPS/Forecast: -0.72
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Syros Pharmaceuticals Inc News
New
3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential
A company’s size does not necessarily dictate the size of it’s returns. On the contrary, if their jobs are done correctly, these penny stocks with potential can generate exponential returns that w...
Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why
Syros Pharmaceuticals, Inc. SYRS shares have skyrocketed 200% in the past three months compared with the industry’s rise of 13.1%. This clinical-stage company is developing its pipeline candidate, ...
Are You Looking for a Top Momentum Pick? Why Syros Pharmaceuticals, Inc. (SYRS) is a Great Choice
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even highe...
Syros Pharmaceuticals, Inc. (SYRS) Is a Great Choice for 'Trend' Investors, Here's Why
While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
